Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers presented at the 2024 annual meetings of the Society of Gynecologic Oncology and American Society of Clinical Oncology including:RUBY Part 1 Subgroup Analyses by MRR Status: Addition of dostarlimab to platinum-based therapy followed by dostarlimab maintenance in advanced endometrial cancerRUBY Part 2: Survival outcomes with addition of dostarlimab to platinum-based therapy followed by dostarlimab plus niraparib maintenance in advanced endometrial cancerSurvival Analyses From Phase III NRG GY018: Carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with advanced endometrial cancerDUO-E: First-line therapy with carboplatin plus paclitaxel plus bevacizumab and durvalumab followed by maintenance with bevacizumab, durvalumab, and olaparib in newly diagnosed endometrial cancerLong-term Follow-up From SIENDO: PFS in TP53 wild-type and preliminary survival by molecular subgroups in patients with endometrial cancer and complete or partial response after ≥12 weeks of first line taxane/carboplatinSubgroup Analyses From the Randomized Phase III MIRASOL: Mirvetuximab soravtansine vs investigator’s choice of chemotherapy in FR𝝰-high platinum-resistant ovarian cancerSubgroup Analyses of Raludotatug Deruxtecan (R-DXd): An anti-CDH6 antibody–drug conjugate in previously treated ovarian cancerPhase III CARACO Trial: Omission of lymphadenectomy in advanced ovarian cancer treated with interval cytoreductive surgery after neoadjuvant chemotherapyinnovaTV 301/ENGOT-cx12/GOG-3057: Tisotumab vedotin vs investigator’s choice of chemotherapy in patients with advanced cervical cancerRandomized, Double-blind, Placebo-controlled Phase III Trial: Addition of pembrolizumab to concurrent chemoradiation in high-risk locally advanced cervical cancerProgram faculty:Floor J. Backes, MDProfessorDirector of Clinical ResearchDivision of Gynecologic OncologyAssociate Fellowship DirectorDepartment of Obstetrics and GynecologyThe Ohio State University College of MedicineThe James Cancer Hospital and Solove Research InstituteColumbus, OhioAngeles Alvarez Secord, MD, MHScProfessor of Obstetrics & GynecologyDivision of Gynecologic OncologyDirector, Gynecologic Oncology Clinical TrialsAssociate Director, Clinical Research, Gynecologic Oncology ProgramDuke Cancer InstituteDuke University Medical CenterDurham, North CarolinaResources:To download the slides associated with this podcast discussion, please visit the program page.

There are no comments yet.

Please log in to write the first comment.